Mirikizumab: A promising breakthrough in Crohn's disease treatment
Open Access
- 6 August 2024
- journal article
- letter
- Published by Wiley in Health Science Reports
- Vol. 7 (8) , e2294
Abstract
Introduction: Crohn's disease (CD) is a chronic, progressive inflammatory bowel disorder characterized by persistent inflammation and noncontiguous “skip lesions” throughout the gastrointestinal tract. With a prevalence of 100–300 cases per 100,000 individuals, CD is most common in Western Europe and North America. Symptoms include abdominal pain, diarrhea, fever, weight loss, and anemia, with severe cases leading to complications such as perianal abscesses and cutaneous fistulas. Treatment involves pharmaceutical interventions, bowel rest, and sometimes surgery, with biological therapies like ustekinumab and mirikizumab gaining prominence.Clinical Trials: The VIVID‐1 trial assessed mirikizumab in patients with moderately to severely active CD. By Week 12, mirikizumab significantly outperformed placebo in clinical response (45.4% vs. 19.6%, p < 0.000001). By Week 52, it showed higher clinical remission rates (54.1% vs. 19.6%) and demonstrated non‐inferiority to ustekinumab in clinical remission (p = 0.51). The SEQUENCE study compared risankizumab to ustekinumab, with risankizumab showing superior reductions in inflammatory markers and higher biologic remission rates at Weeks 8, 24, and 48. Both treatments had similar safety profiles, with common adverse events including COVID‐19, anemia, and headache.Conclusion: Mirikizumab, based on the VIVID‐1 trial outcomes, is a promising addition to CD therapy. It demonstrated significant clinical responses and remission rates, warranting further research on its long‐term efficacy and safety. Updating professional guidelines and addressing affordability will ensure broader access and improved management of CD.Keywords
This publication has 8 references indexed in Scilit:
- OP35 Efficacy of mirikizumab in comparison to ustekinumab in patients with moderate to severe Crohn’s disease: Results from the phase 3 VIVID 1 studyJournal of Crohn's and Colitis, 2024
- DOP10 Risankizumab Versus Ustekinumab for the Achievement of Endoscopic Outcomes in Patients With Moderate-to-Severe Crohn’s Disease: Results From the Phase 3b SEQUENCE TrialJournal of Crohn's and Colitis, 2024
- Temporal trends in surgery for Crohn’s disease: a ten-year single-center retrospective studyInternational Journal of Colorectal Disease, 2023
- Blockade of IL-23: What is in the Pipeline?Journal of Crohn's and Colitis, 2022
- StatPearls2021
- Safety of selective IL‐23p19 inhibitors for the treatment of psoriasisJournal of the European Academy of Dermatology and Venereology, 2019
- Crohn's diseaseThe Lancet, 2017
- Epidemiology and risk factors for IBDNature Reviews Gastroenterology & Hepatology, 2015